End-of-day quote
Shanghai S.E.
06:00:00 2024-07-16 pm EDT
|
5-day change
|
1st Jan Change
|
6.04
CNY
|
+0.50%
|
|
+0.50%
|
-36.69%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,835
|
3,586
|
6,929
|
9,595
|
6,085
|
4,207
|
Enterprise Value (EV)
1 |
2,299
|
2,673
|
6,176
|
9,281
|
6,439
|
4,491
|
P/E ratio
|
19.5
x
|
20.8
x
|
34.2
x
|
32.9
x
|
19.4
x
|
18
x
|
Yield
|
2.34%
|
1.85%
|
-
|
0.92%
|
1.6%
|
1.68%
|
Capitalization / Revenue
|
1.96
x
|
1.97
x
|
2.62
x
|
3.1
x
|
1.95
x
|
1.72
x
|
EV / Revenue
|
1.59
x
|
1.47
x
|
2.33
x
|
3
x
|
2.06
x
|
1.83
x
|
EV / EBITDA
|
9.35
x
|
7.68
x
|
12.8
x
|
16.4
x
|
12.8
x
|
10.8
x
|
EV / FCF
|
-155
x
|
-8.4
x
|
-397
x
|
-20.4
x
|
55
x
|
42.6
x
|
FCF Yield
|
-0.65%
|
-11.9%
|
-0.25%
|
-4.9%
|
1.82%
|
2.35%
|
Price to Book
|
2.06
x
|
2.23
x
|
3.93
x
|
4.62
x
|
2.73
x
|
1.75
x
|
Nbr of stocks (in thousands)
|
441,609
|
441,609
|
441,609
|
441,569
|
441,569
|
441,002
|
Reference price
2 |
6.420
|
8.120
|
15.69
|
21.73
|
13.78
|
9.540
|
Announcement Date
|
3/28/19
|
3/30/20
|
3/29/21
|
4/20/22
|
4/18/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,450
|
1,817
|
2,645
|
3,097
|
3,119
|
2,453
|
EBITDA
1 |
245.9
|
347.9
|
480.7
|
566.1
|
502.7
|
417
|
EBIT
1 |
174.9
|
265.2
|
371.6
|
443.8
|
370.2
|
275.3
|
Operating Margin
|
12.06%
|
14.6%
|
14.05%
|
14.33%
|
11.87%
|
11.22%
|
Earnings before Tax (EBT)
1 |
208.7
|
288.9
|
390.2
|
483.7
|
399.4
|
300.5
|
Net income
1 |
147.1
|
170.1
|
202.8
|
291.4
|
311.7
|
230.9
|
Net margin
|
10.14%
|
9.36%
|
7.67%
|
9.41%
|
9.99%
|
9.41%
|
EPS
2 |
0.3300
|
0.3900
|
0.4592
|
0.6600
|
0.7100
|
0.5300
|
Free Cash Flow
1 |
-14.85
|
-318
|
-15.57
|
-455.2
|
117
|
105.4
|
FCF margin
|
-1.02%
|
-17.5%
|
-0.59%
|
-14.7%
|
3.75%
|
4.3%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
23.27%
|
25.27%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
37.52%
|
45.65%
|
Dividend per Share
2 |
0.1500
|
0.1500
|
-
|
0.2000
|
0.2200
|
0.1600
|
Announcement Date
|
3/28/19
|
3/30/20
|
3/29/21
|
4/20/22
|
4/18/23
|
4/19/24
|
Fiscal Period: December |
2023 Q1
|
---|
Net sales
1 |
686.9
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
85.12
|
Net margin
|
12.39%
|
EPS
2 |
0.1900
|
Dividend per Share
|
-
|
Announcement Date
|
4/18/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
354
|
283
|
Net Cash position
1 |
537
|
913
|
753
|
314
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
0.7038
x
|
0.6798
x
|
Free Cash Flow
1 |
-14.9
|
-318
|
-15.6
|
-455
|
117
|
105
|
ROE (net income / shareholders' equity)
|
12.2%
|
11.5%
|
11.5%
|
13.2%
|
12.6%
|
10.4%
|
ROA (Net income/ Total Assets)
|
5.79%
|
5.58%
|
5.79%
|
6.02%
|
5.09%
|
4.12%
|
Assets
1 |
2,542
|
3,050
|
3,505
|
4,841
|
6,126
|
5,608
|
Book Value Per Share
2 |
3.110
|
3.630
|
3.990
|
4.700
|
5.050
|
5.450
|
Cash Flow per Share
2 |
1.650
|
2.440
|
2.810
|
2.280
|
0.9500
|
1.150
|
Capex
1 |
180
|
219
|
332
|
654
|
296
|
228
|
Capex / Sales
|
12.41%
|
12.05%
|
12.56%
|
21.12%
|
9.5%
|
9.3%
|
Announcement Date
|
3/28/19
|
3/30/20
|
3/29/21
|
4/20/22
|
4/18/23
|
4/19/24
|
|
1st Jan change
|
Capi.
|
---|
| -36.69% | 361M | | +28.34% | 2.62B | | +28.15% | 2.48B | | -47.44% | 2.31B | | +36.67% | 2.07B | | -31.46% | 2.04B | | -24.50% | 1.61B | | +13.96% | 1.43B | | +36.22% | 1.33B | | +18.21% | 1.27B |
Medical Supplies
|